[go: up one dir, main page]

EA201490949A1 - Ингибиторы киназ - Google Patents

Ингибиторы киназ

Info

Publication number
EA201490949A1
EA201490949A1 EA201490949A EA201490949A EA201490949A1 EA 201490949 A1 EA201490949 A1 EA 201490949A1 EA 201490949 A EA201490949 A EA 201490949A EA 201490949 A EA201490949 A EA 201490949A EA 201490949 A1 EA201490949 A1 EA 201490949A1
Authority
EA
Eurasian Patent Office
Prior art keywords
kinaz
inhibitors
kinaz inhibitors
mapk
compounds
Prior art date
Application number
EA201490949A
Other languages
English (en)
Other versions
EA025268B1 (ru
Inventor
Моника Бодил Ван Нил
Николас Чарльз Рэй
Лилиан Алькараз
Терри Аарон Панчал
Эндрю Стивен Роберт Дженнингс
Элисабетта Армани
Эндрю Питер Кридлэнд
Кристофер Херли
Original Assignee
КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47471708&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201490949(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. filed Critical КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А.
Publication of EA201490949A1 publication Critical patent/EA201490949A1/ru
Publication of EA025268B1 publication Critical patent/EA025268B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/02—Formic acid
    • C07C53/06—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Соединения формулы (I) или их фармацевтически приемлемые соли, где R, W, A, Y и Rявляются такими, как определено в описании изобретения, являются ингибиторами киназы MAPK р38, полезными в качестве противовоспалительных агентов при лечении, в частности, заболеваний дыхательных путей.
EA201490949A 2011-12-09 2012-12-05 Ингибиторы киназ EA025268B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11192871 2011-12-09
EP12187931 2012-10-10
PCT/EP2012/074446 WO2013083604A1 (en) 2011-12-09 2012-12-05 Kinase inhibitors

Publications (2)

Publication Number Publication Date
EA201490949A1 true EA201490949A1 (ru) 2014-11-28
EA025268B1 EA025268B1 (ru) 2016-12-30

Family

ID=47471708

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490949A EA025268B1 (ru) 2011-12-09 2012-12-05 Ингибиторы киназ

Country Status (35)

Country Link
US (5) US8907094B2 (ru)
EP (1) EP2788349B1 (ru)
JP (1) JP6128449B2 (ru)
KR (1) KR101994381B1 (ru)
CN (3) CN104039787B (ru)
AR (1) AR089189A1 (ru)
AU (1) AU2012347350C1 (ru)
BR (1) BR112014013760A2 (ru)
CA (1) CA2858447C (ru)
CL (1) CL2014001486A1 (ru)
CO (1) CO6970602A2 (ru)
CY (1) CY1118340T1 (ru)
DK (1) DK2788349T3 (ru)
EA (1) EA025268B1 (ru)
ES (1) ES2612259T3 (ru)
GE (1) GEP201706735B (ru)
HK (2) HK1222647A1 (ru)
HR (1) HRP20161714T1 (ru)
HU (1) HUE029826T2 (ru)
IL (1) IL232958A (ru)
LT (1) LT2788349T (ru)
ME (1) ME02624B (ru)
MX (1) MX359200B (ru)
MY (1) MY170656A (ru)
PE (1) PE20141370A1 (ru)
PH (1) PH12014501277A1 (ru)
PL (1) PL2788349T3 (ru)
PT (1) PT2788349T (ru)
RS (1) RS55602B1 (ru)
SG (1) SG11201402985VA (ru)
SI (1) SI2788349T1 (ru)
TW (1) TWI618703B (ru)
UA (1) UA115320C2 (ru)
WO (1) WO2013083604A1 (ru)
ZA (1) ZA201404156B (ru)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6145849B2 (ja) * 2011-12-09 2017-06-14 チエシ ファルマスーティシ エス．ピー．エー． キナーゼ阻害剤
BR112014013178A2 (pt) * 2011-12-09 2017-06-13 Chiesi Farm Spa composto, composição farmacêutica e uso de um composto
KR101994381B1 (ko) 2011-12-09 2019-06-28 키에시 파르마슈티시 엣스. 피. 에이. 키나아제 억제제
GB201214750D0 (en) 2012-08-17 2012-10-03 Respivert Ltd Compounds
US20150210722A1 (en) 2012-08-29 2015-07-30 Respivert Limited Kinase inhibitors
WO2014033447A2 (en) 2012-08-29 2014-03-06 Respivert Limited Kinase inhibitors
WO2014033449A1 (en) 2012-08-29 2014-03-06 Respivert Limited Kinase inhibitors
EP2925742B1 (en) 2012-11-16 2016-10-26 Respivert Limited Kinase inhibitors
EP2970190A1 (en) 2013-03-14 2016-01-20 Respivert Limited Kinase inhibitors
WO2014162121A1 (en) 2013-04-02 2014-10-09 Topivert Pharma Limited Kinase inhibitors based upon n-alkyl pyrazoles
BR112015024678B1 (pt) 2013-04-02 2023-02-23 Oxular Acquisitions Limited Composto inibidor da cinase, formulação farmacêutica que compreende o mesmo, seus usos, processo para sua preparação e intermediários
US9573949B2 (en) 2013-06-06 2017-02-21 Chiesi Farmaceutici S.P.A. Derivatives of [1, 2, 4] triazolo [4, 3-a] pyridine as P38—MAP kinase inhibitors
CN105377847A (zh) 2013-06-06 2016-03-02 奇斯药制品公司 激酶抑制剂
BR112015029462A8 (pt) * 2013-06-06 2023-03-21 Chiesi Farm Spa Inibidores de quinase
EP2818471A1 (en) * 2013-06-27 2014-12-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5
JP6514703B2 (ja) 2013-12-20 2019-05-15 トピバート ファーマ リミテッド キナーゼインヒビターとして有用な尿素誘導体
AU2015216705B2 (en) 2014-02-14 2019-03-28 Respivert Limited Pyrazolyl-ureas as kinase inhibitors
MA40775A (fr) 2014-10-01 2017-08-08 Respivert Ltd Dérivé d'acide 4-(4-(4-phényluréido-naphtalén -1-yl) oxy-pyridin-2-yl) amino-benzoïque utilisé en tant qu'inhibiteur de la kinase p38
US10206949B2 (en) 2015-09-21 2019-02-19 Ofer Agam Composition that relieves heartburn, GERD and hangovers
EP3394059B1 (en) 2015-12-23 2020-11-25 Chiesi Farmaceutici S.p.A. 1-(3-tert-butyl-phenyl)-3-(4-([1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro- naphthalen-1-yl)-urea derivatives and their use as p38 mapk inhibitors
MA44131A (fr) 2015-12-23 2021-05-26 Chiesi Farm Spa Dérivés de 1-(3-tert-butyl-2h-pyrazol-5-yl or 5-tert-butyl-isoxaol-3-yl)-3-(4-([1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalenyl) urée et leur utlisation en tant qu'inhibiteurs de p38 mapk
EP3394058B1 (en) 2015-12-23 2020-10-14 Chiesi Farmaceutici S.p.A. N-[3-(3-{4-[[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl} -ureido)-phenyl]-methanesulfonamide derivatives and their use as p38 mapk inhibitors
AU2017245888B2 (en) 2016-04-06 2021-05-13 Oxular Acquisitions Limited Kinase inhibitors
US10364245B2 (en) * 2017-06-07 2019-07-30 Chiesi Farmaceutici S.P.A. Kinase inhibitors
CA3078232A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. Use of p38 inhibitors to reduce expression of dux4
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CN108424372B (zh) * 2018-05-11 2021-08-10 浙江华贝药业有限责任公司 2，2，2-三氟-n-[(s)-4-羰基四氢萘-1-基]-乙酰胺的纯化工艺
CN108707086B (zh) * 2018-05-15 2021-08-10 浙江华贝药业有限责任公司 一种(1s，4s)-n-（4-羟基四氢萘-1-基）叔丁氧基碳酰胺的纯化工艺
AR116628A1 (es) 2018-10-18 2021-05-26 Syngenta Crop Protection Ag Compuestos microbiocidas
JP2023516197A (ja) 2020-03-05 2023-04-18 シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト 殺菌性組成物
CN112174870B (zh) * 2020-10-12 2023-07-21 蔡霈 (r)-1-烷烃酰基-2-取代吡咯烷-2-甲酰胺的制备方法及其药用用途

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
US5756533A (en) 1995-03-10 1998-05-26 G.D. Searle & Co. Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
WO1997002289A1 (en) 1995-07-06 1997-01-23 Zeneca Limited Peptide inhibitors of fibronectine
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
YU25500A (sh) 1999-05-11 2003-08-29 Pfizer Products Inc. Postupak za sintezu analoga nukleozida
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
EP1241176A1 (en) 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
JP2005507367A (ja) * 2001-04-13 2005-03-17 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド １，４−二置換ベンゾ縮合化合物
CA2470813A1 (en) 2001-12-20 2003-07-03 Bayer Healthcare Ag 1,4-dihydro-1,4-diphenylpyridine derivatives
CA2494824A1 (en) * 2002-08-08 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Fluorinated phenyl-naphthalenyl-urea compounds as inhibitors of cytokines involved in inflammatory processes
JP2006517580A (ja) * 2003-02-14 2006-07-27 ファイザー・プロダクツ・インク 抗炎症化合物としてのトリアゾロピリジン
SE0302487D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
US7880000B2 (en) * 2004-05-07 2011-02-01 Amgen Inc. Protein kinase modulators and method of use
EP1761520B1 (en) 2004-06-23 2008-07-09 Eli Lilly And Company Kinase inhibitors
EP1609789A1 (en) 2004-06-23 2005-12-28 Eli Lilly And Company Ureido-pyrazole derivatives and their use as kinase inhibitors
GB0418015D0 (en) * 2004-08-12 2004-09-15 Pfizer Ltd New compounds
DE602005010714D1 (de) 2004-08-12 2008-12-11 Pfizer Der p38-map-kinase
WO2006018727A2 (en) 2004-08-18 2006-02-23 Pharmacia & Upjohn Company Llc Triazolopyridine compounds useful for the treatment of inflammation
GB0502258D0 (en) 2005-02-03 2005-03-09 Argenta Discovery Ltd Compounds and their use
JP2008545756A (ja) 2005-06-03 2008-12-18 バイエル・ヘルスケア・アクチェンゲゼルシャフト 癌化学療法剤として有用な１−メチル−１ｈ−ピラゾール−４−カルボキサミド類
WO2007091152A1 (en) 2006-02-09 2007-08-16 Pfizer Limited Triazolopyridine compounds
CN101146029B (zh) * 2006-09-13 2011-12-28 华为技术有限公司 一种分组重排序方法和系统
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US7915268B2 (en) 2006-10-04 2011-03-29 Wyeth Llc 8-substituted 2-(benzimidazolyl)purine derivatives for immunosuppression
US7790741B2 (en) 2006-10-06 2010-09-07 Abbott Laboratories Imidazothiazoles and imidazoxazoles
WO2008125014A1 (fr) 2007-04-13 2008-10-23 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. Composés d'urée, leurs procédés de préparation et leurs utilisations pharmaceutiques
US8202899B2 (en) 2007-07-25 2012-06-19 Array Biopharma Inc. Pyrazole urea derivatives used as kinase inhibitors
US20110207729A1 (en) 2007-08-10 2011-08-25 Astellas Pharma Inc. Bicyclic acylguanidine derivative
TWI496779B (zh) 2008-08-19 2015-08-21 Array Biopharma Inc 作為ｐｉｍ激酶抑制劑之三唑吡啶化合物
SG171993A1 (en) 2008-12-08 2011-07-28 Gilead Connecticut Inc Imidazopyrazine syk inhibitors
US8299073B2 (en) * 2008-12-11 2012-10-30 Respivert Ltd. P38 MAP kinase inhibitors
JP5583694B2 (ja) 2009-01-05 2014-09-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節するピロリジン化合物
MA33128B1 (fr) 2009-02-17 2012-03-01 Chiesi Farma Spa Derives de triazolopyridine utilises comme inhibiteurs de la p38 map kinase
US9127016B2 (en) 2009-03-20 2015-09-08 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecule inhibitors of Dusp6 and uses therefor
JP4720961B2 (ja) 2009-08-12 2011-07-13 コニカミノルタホールディングス株式会社 表示パネルの製造方法
EP2308866A1 (de) 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide
GB0921731D0 (en) 2009-12-11 2010-01-27 Respivert Ltd Theraputic uses
GB201005589D0 (en) * 2010-04-01 2010-05-19 Respivert Ltd Novel compounds
US9024041B2 (en) * 2010-04-08 2015-05-05 Respivert Ltd. P38 MAP kinase inhibitors
GB201009731D0 (en) * 2010-06-10 2010-07-21 Pulmagen Therapeutics Inflamma Kinase inhibitors
BR112014013178A2 (pt) 2011-12-09 2017-06-13 Chiesi Farm Spa composto, composição farmacêutica e uso de um composto
JP6145849B2 (ja) 2011-12-09 2017-06-14 チエシ ファルマスーティシ エス．ピー．エー． キナーゼ阻害剤
KR101994381B1 (ko) * 2011-12-09 2019-06-28 키에시 파르마슈티시 엣스. 피. 에이. 키나아제 억제제
US9573949B2 (en) 2013-06-06 2017-02-21 Chiesi Farmaceutici S.P.A. Derivatives of [1, 2, 4] triazolo [4, 3-a] pyridine as P38—MAP kinase inhibitors
BR112015029462A8 (pt) 2013-06-06 2023-03-21 Chiesi Farm Spa Inibidores de quinase
CN105377847A (zh) 2013-06-06 2016-03-02 奇斯药制品公司 激酶抑制剂

Also Published As

Publication number Publication date
EA025268B1 (ru) 2016-12-30
HRP20161714T1 (hr) 2017-02-10
CO6970602A2 (es) 2014-06-13
AU2012347350C1 (en) 2017-01-19
CN105968110B (zh) 2018-04-27
CN105968110A (zh) 2016-09-28
SI2788349T1 (sl) 2017-01-31
KR20140105516A (ko) 2014-09-01
TWI618703B (zh) 2018-03-21
CN105503861B (zh) 2017-08-01
CN104039787B (zh) 2016-06-29
AU2012347350A1 (en) 2014-07-03
GEP201706735B (en) 2017-09-25
IL232958A (en) 2017-08-31
WO2013083604A1 (en) 2013-06-13
US9139584B2 (en) 2015-09-22
LT2788349T (lt) 2016-12-27
AR089189A1 (es) 2014-08-06
PT2788349T (pt) 2017-02-02
US8907094B2 (en) 2014-12-09
US20150344475A1 (en) 2015-12-03
EP2788349A1 (en) 2014-10-15
CL2014001486A1 (es) 2014-11-14
JP6128449B2 (ja) 2017-05-17
PE20141370A1 (es) 2014-10-17
US20130150343A1 (en) 2013-06-13
PH12014501277B1 (en) 2014-09-08
TW201336833A (zh) 2013-09-16
MX2014006724A (es) 2014-08-29
ME02624B (me) 2017-06-20
PL2788349T3 (pl) 2017-04-28
EP2788349B1 (en) 2016-10-26
DK2788349T3 (en) 2017-01-30
ES2612259T3 (es) 2017-05-16
CA2858447C (en) 2020-10-27
HK1222647A1 (zh) 2017-07-07
SG11201402985VA (en) 2014-08-28
MX359200B (es) 2018-09-19
UA115320C2 (uk) 2017-10-25
CY1118340T1 (el) 2017-06-28
CA2858447A1 (en) 2013-06-13
RS55602B1 (sr) 2017-06-30
KR101994381B1 (ko) 2019-06-28
US9145413B2 (en) 2015-09-29
HK1200828A1 (en) 2015-08-14
MY170656A (en) 2019-08-24
US20160229852A1 (en) 2016-08-11
CN105503861A (zh) 2016-04-20
NZ625965A (en) 2016-08-26
BR112014013760A2 (pt) 2017-06-13
HUE029826T2 (en) 2017-04-28
IL232958A0 (en) 2014-08-03
AU2012347350B2 (en) 2016-09-08
US9315503B2 (en) 2016-04-19
JP2015500260A (ja) 2015-01-05
US20150080375A1 (en) 2015-03-19
CN104039787A (zh) 2014-09-10
US20140323470A1 (en) 2014-10-30
US9527846B2 (en) 2016-12-27
PH12014501277A1 (en) 2014-09-08
ZA201404156B (en) 2016-07-27

Similar Documents

Publication Publication Date Title
EA201490949A1 (ru) Ингибиторы киназ
UY39630A (es) Inhibidores de bromodominios
CY1122498T1 (el) Δευτεριωμενα παραγωγα ιβακαφτορης
CY1122266T1 (el) Ενωσεις 3-αμινοκυκλοαλκυλιου ως ror-gamma-t αναστολεις και χρησεις αυτων
EA201792116A1 (ru) Ингибитор янус-киназы
CY1120318T1 (el) Υποκατεστημενες βενζυλινδαζολες για χρηση ως αναστολεις κινασης bub1 στη θεραπευτικη αντιμετωπιση υπερπολλαπλασιαστικων ασθενειων
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
PH12014501278A1 (en) Kinase inhibitors
UA111382C2 (uk) Інгібітори протеїнкінази
EA201791576A1 (ru) Ингибитор jak
BR112015000704A2 (pt) imidazotriazinacarbonitrilas úteis como inibidores de quinase
TR201905814T4 (tr) Jak inhibitörü olarak bipirazol tuzu.
EA201991884A3 (ru) Ингибиторы g12c kras
BR112015029970A2 (pt) inibidores de cinase
EA201400333A1 (ru) Бензонитрильные производные в качестве ингибиторов киназ
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
SMT201300109B (it) Imidazopiridazincarbonitrili utili come inibitori di chinasi
BR112015022643A2 (pt) inibidores diidro-pirrolpiridinona
EA201591363A1 (ru) Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
EA201301301A1 (ru) Производные тиазола
UA113215C2 (xx) Похідні проліків (e)-n-метил-n-((3-метилбензофуран-2-іл)метил)-3-(7-оксо-5,6,7,8-тетрагідро-1,8-нафтиридин-3-іл)акриламіду
BR112015029462A2 (pt) Inibidores de quinase
GB201209587D0 (en) Therapeutic compounds